October 31, 2023 Experience GSK exclusive license agreement for HS-20089 with Hansoh Pharma We advised GSK on the transaction
October 30, 2023 Experience GSK collaboration extension and new data licensing agreement with 23andMe We advised GSK on the transaction
October 23, 2023 Experience Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant We are advising Roche on the acquisition
September 19, 2023 Experience RayzeBio $358 million IPO The stock is listed on the Nasdaq Global Market
August 15, 2023 Experience SSI Strategy acquisition of NDA Group We advised SSI Strategy on the acquisition
July 28, 2023 Experience Immedica Pharma acquisition of pegzilarginase assets from Aeglea We advised Immedica on the transaction
July 28, 2023 Experience BMS $35 million investment in Immatics We advised Immatics on the private placement of ordinary shares
June 28, 2023 Experience Centogene strategic collaboration with Lifera We are advising Centogene on its joint venture with and convertible debt investment by Lifera
June 27, 2023 Experience Noile-Immune Biotech ¥3.1 billion global IPO The shares are listed on the Tokyo Stock Exchange
June 5, 2023 Experience Oculis Holding $40.25 million debut equity offering The shares are listed on the Nasdaq Global Market